AI English summary of an SEC filing — figures as filed
Agilent Technologies AAgilent said net revenue for the 3 and 9 months ended July 31, 2024 fell 6% and 7%, respectively, from the same periods last year, to $1,578 million and $4,809 million. The company said Agilent CrossLab revenue rose 4% and 5% over the same periods.
Key points
AI summaryAgilent said net revenue for the 3 and 9 months ended July 31, 2024 fell 6% and 7%, respectively, from the same periods last year, to $1,578 million and $4,809 million. The company said Agilent CrossLab revenue rose 4% and 5% over the same periods.
Agilent said net income was $282 million for the 3 months and $938 million for the 9 months, versus $111 million and $765 million in the same periods last year. Cash provided by operating activities for the 9 months was $1,270 million, compared with $1,256 million a year earlier.
Agilent said it repurchased and retired 5.991 million shares for $815 million over 9 months under the 2023 repurchase program, and that approximately $709 million of authorization remained as of July 31, 2024. The company also said it entered into an agreement on July 21, 2024 to acquire BIOVECTRA for $925 million in cash.
The company said it announced the FY24 Plan in fiscal 2024 in Q3, which included a reduction of about 500 employees, or about 3% of its global workforce. It expects the plan to reduce annual cost of sales and operating expenses by about $100 million when completed, and said it recorded related costs of about $67 million in the 3 and 9 months.
Key figures
Quarter ended July 31, 2024
- Revenue
- $1.6B
- Operating income
- $333M
- Net income
- $282M
- EPS
- $0.97
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Quarterly and 9-month net revenue and segment changes
Agilent said net revenue for the 3 and 9 months ended July 31, 2024 fell 6% and 7%, respectively, from the same periods last year, to $1,578 million and $4,809 million. The company said Agilent CrossLab revenue rose 4% and 5% over the same periods.
Source · Based on the MD&A text of the filing
Net income and operating cash flow
Agilent said net income was $282 million for the 3 months and $938 million for the 9 months, versus $111 million and $765 million in the same periods last year. Cash provided by operating activities for the 9 months was $1,270 million, compared with $1,256 million a year earlier.
Source · Based on the MD&A text of the filing
Share repurchases and BIOVECTRA acquisition agreement
Agilent said it repurchased and retired 5.991 million shares for $815 million over 9 months under the 2023 repurchase program, and that approximately $709 million of authorization remained as of July 31, 2024. The company also said it entered into an agreement on July 21, 2024 to acquire BIOVECTRA for $925 million in cash.
Source · Based on the MD&A text of the filing
FY24 Plan restructuring
The company said it announced the FY24 Plan in fiscal 2024 in Q3, which included a reduction of about 500 employees, or about 3% of its global workforce. It expects the plan to reduce annual cost of sales and operating expenses by about $100 million when completed, and said it recorded related costs of about $67 million in the 3 and 9 months.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…